JSJeffrey R. Strich

Jeffrey R. Strich

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jeffrey R. Strich has a total of 190 co-authors. Here are the top co-authors by number of shared publications:

  • Seth Warner

    Critical Care Medicine Department, Clinical Center, National Institutes of Health , Bethesda, Maryland

    5 shared publications
  • Cumhur Y Demirkale

    National Institutes of Health , Bethesda, Md

    4 shared publications
  • Marcos J. Ramos-Benitez

    Basic Science Department, Microbiology, Ponce Health Sciences University, Ponce, PR

    4 shared publications
  • Anthony F Suffredini

    Critical Care Medicine Department, National Institutes of Health Clinical Center , Bethesda, Maryland

    3 shared publications
  • Christopher King

    Advanced Lung Disease and Lung Transplant Program, Inova Fairfax Hospital, Falls Church, VA, USA

    3 shared publications
  • Daniel S Chertow

    Critical Care Medicine Department, Clinical Center, National Institutes of Health , Bethesda, Maryland

    3 shared publications

Latest Publications

  • Open Access

    Association of CD16hiCD62Llo Neutrophils with Disease Severity and Impact of SYK Inhibition in Sepsis

    by Xianglan Yao, Heather L Teague, Lauren E Knabe, Raquel Santana da Cruz, Trenton Williams, Merte Lemma Woldehanna, Ernest Evans, Amir Hobson, Jared D Wilkinson, Cumhur Yusuf Demirkale, et al.

    Background: Sepsis is a global health priority that leads to significant morbidity and mortality. Therefore, there is an urgent need to better understand sepsis pathogenesis to inform diagnosis, prognosis, and identify novel host-directed therapeutics. Methods: Flow cytometry was performed on 35 sepsis patients and 18 healthy controls to characterize neutrophils and neutrophil subsets and their association with clinical outcomes. Additionally, purified neutrophils from 20 sepsis patients were stimulated with lipopolysaccharide (LPS), with and without R406 treatment, to assess changes in neutrophil populations and the impact of spleen tyrosine kinase (SYK) inhibition. Results: We found that patients with sepsis have increased levels of circulating CD16hi/CD62Llo neutrophils that correlate with disease severity, including the need for intensive care unit admission, vasopressors, and mortality. This CD16hi/CD62Llo population expressed lower CD10 and CD62L and higher CD33 compared to healthy controls. Additionally, compared to healthy donors, the sepsis CD16hi/CD62Llo population had higher levels of SYK. Finally, ex vivo stimulation of sepsis neutrophils with LPS increased the percentage of CD16hi/CD62Llo population and the shift in this population could be prevented with SYK inhibition. Conclusion: These data suggest that CD16hi/CD62Llo neutrophils may contribute to sepsis pathogenesis and that SYK is a potential therapeutic target that can modulate this neutrophil population, but further mechanistic studies are warranted to establish a causal role in sepsis.

  • Impact of Fostamatinib on Inflammatory Biomarkers in Hospitalized Patients With COVID-19

    by Raquel S. Da Cruz, Heather L. Teague, Marcos J. Ramos-Benitez, Sonya J. Malavez-Cajigas, Trenton Williams, Rui Miao, Xin Tian, Gefei Lin, Laurence W. Busse, Akram Khan, et al.

    OBJECTIVES: Understanding the mechanistic impact of fostamatinib, a spleen tyrosine kinase inhibitor, in severe COVID-19 using biomarkers associated with disease severity is crucial for the development of host-directed therapeutics. We analyzed samples from a randomized clinical trial to investigate the impact of fostamatinib on multiple inflammatory biomarkers associated with COVID-19 disease severity. DESIGN: Secondary analyses of biomarkers from a randomized clinical trial. SETTING: Multicenter randomized clinical trial. PATIENTS: A total of 400 adults hospitalized with COVID-19 were enrolled in a phase 3 randomized clinical trial. Absolute neutrophil counts (ANCs) were analyzed across 392 patients and biomarkers were measured in 190 patients with available plasma samples. INTERVENTIONS: Adults hospitalized with COVID-19 were randomized to receive either fostamatinib (150 mg bid) or placebo. ANCs and 24 biomarkers were assessed at day 0 and over time using a multiplexed Meso Scale Discovery assay (Meso Scale Diagnostics LLC, Rockville, MD). MEASUREMENTS AND MAIN RESULTS: At day 0, participants with World Health Organization ordinal scale 5–7 had elevated ANC counts, compared with ordinal scale 4. In addition, the levels of neutrophil-associated biomarkers, inflammatory cytokines, and mediators of endothelial dysfunction at day 0 were increased in the participants who were ordinal scale 5–7 vs. ordinal scale 4. Randomization to fostamatinib compared with placebo resulted in a decrease in ANC and several neutrophil-associated biomarkers, pro-inflammatory cytokines, and mediators of endothelial dysfunction/tissue damage. This differential finding was also demonstrated in a subgroup of patients ( n = 85) with a hypoinflammatory phenotype. LIMITATIONS: Missing plasma samples and neutral phase 3 trial results. CONCLUSIONS: Randomization to fostamatinib resulted in lower neutrophil counts and levels of circulating biomarkers in hospitalized patients with COVID-19; however, the observed impact of fostamatinib was modest compared with prior studies.

  • Open Access

    Low-density neutrophil heterogeneity and spleen tyrosine kinase as therapeutic targets in sepsis

    by Heather L. Teague, Lauren Knabe, Raquel S. Da Cruz, Xianglan Yao, Kiana C. Allen, Trenton Williams, Cumhur Y. Demirkale, Merte Woldehanna, Ernest Evans, Amir Hobson, et al.

    Sepsis is a leading cause of death for which host-directed therapies are urgently needed. We performed high-dimensional flow cytometry, measurement of soluble biomarkers, and lipopolysaccharide (LPS) stimulation of neutrophils to characterize neutrophil heterogeneity and function in patients with sepsis. We observed that in patients with sepsis, low-density neutrophils (LDNs) are elevated and phenotypically diverse populations of innate immune cells with varying degrees of maturity and myeloperoxidase expression. Spleen tyrosine kinase (SYK) expression was found to be higher in whole blood neutrophils and LDNs of patients with sepsis compared with healthy donors. Importantly, SYK + LDNs associated with increased levels of intracellular myeloperoxidase (MPO) and soluble biomarkers. Furthermore, SYK + LDNs correlated with clinical outcomes of sepsis disease severity, including sequential organ failure assessment score, mechanical ventilation, and vasopressors. Functionally, the SYK inhibitor R406 suppressed changes in neutrophil features of activation from normal-density neutrophils and LDNs, including the SYK + and SYK – neutrophil subsets, and MPO release from LDNs following LPS stimulation of sepsis neutrophils. Combined, these results establish LDNs as a heterogenous population of neutrophils that express high levels of SYK and support SYK inhibition as a potentially novel therapeutic target aimed at suppressing overactive neutrophils in sepsis.


  • Breaking the Stalemate: Advancing Sepsis Therapeutics Beyond Supportive Care

    by Jeffrey R. Strich, Heather L. Teague, Xianglan Yao, Raquel S. Cruz, Richard W. Childs


  • Elevated Spleen Tyrosine Kinase in Low-Density Neutrophils During Bacterial Sepsis in a Nonhuman Primate Model

    by Heather L Teague, Seth Warner, Andrew P Platt, Sydney Stein, Marcos J Ramos-Benitez, Sabrina Ramelli, Shelly Curran, Izabella Lach, Kiana Allen, Heritage Adetola, et al.

    Background: Sepsis is a leading cause of death worldwide. Identifying novel host-directed therapeutic targets may improve sepsis outcomes. Methods: Six nonhuman primates were infected with Klebsiella pneumoniae to induce septic shock and provided supportive care for up to 72 hours. Flow cytometry was used to characterize whole-blood neutrophils (WBNs) and low-density neutrophils (LDNs) at time 0 (T0), T6, T24, and T48 hours postinfection, and postmortem examination (ie, necropsy). Dimensional reduction with clustering via FlowSOM and traditional gating strategies were used to compare WBNs to LDNs and delineate spleen tyrosine kinase (SYK) expression across neutrophils subsets. We measured soluble biomarkers of end-organ dysfunction and neutrophil activation, and quantified SYK and myeloperoxidase in tissue. Results: At T6, we identified populations of active immature WBNs and a population of LDNs not detected at baseline. At T24, neutrophil heterogeneity increased across WBNs and LDNs with differential expression of myeloperoxidase (MPO). Compared to WBNs, LDNs were more activated with increased MPO expression. At T6, SYK expression surged in WBNs and LDNs and SYK+ WBNs and LDNs expressed higher levels of MPO and lactoferrin compared to SYK− neutrophils. Circulating levels of SYK+ LDNs significantly correlated with serum creatinine levels, indicative of acute kidney injury; prolonged prothrombin time and decreased fibrinogen, indicative of consumptive coagulopathy; and SYK expression in tissues. Conclusions: Bacterial sepsis leads to heterogenous populations of circulating neutrophils, including LDNs. Elevated SYK expression in WBNs and LDNs correlates with end-organ dysfunction, highlighting SYK as a potential therapeutic target in bacterial sepsis.


  • Surfactant Protein D and Club Cell Secretory Protein as Biomarkers of Disease Severity and Fostamatinib Efficacy in Severe COVID-19

    by Marcos J. Ramos-Benitez, Rui Miao, Andrea P. Rivera-Torres, Mercedes Lacourt-Ventura, Sonya J. Malavez-Cajigas, Xin Tian, Heather L. Teague, Wilfredo De Jesus-Rojas, Robert Reger, Anthony F. Suffredini, et al.

    OBJECTIVES: The objective of the study was to evaluate whether epithelial injury biomarkers—club cell secretory protein (CC16), surfactant protein D (SPD), surfactant protein A (SPA), and receptor for advanced glycation end-products (RAGE)—could prognosticate disease severity and predict treatment responses in hospitalized COVID-19 patients receiving fostamatinib. DESIGN: Retrospective analysis of samples collected from a randomized, placebo-controlled clinical trial evaluating the safety and efficacy of fostamatinib in hospitalized COVID-19 patients. SETTING: Hospitalized patients in a multicenter clinical trial. PATIENTS: Hospitalized COVID-19 patients requiring supplemental oxygen. INTERVENTIONS: Longitudinal measurement of soluble biomarkers of epithelial injury in patients enrolled in the clinical trial. MEASUREMENTS AND MAIN RESULTS: Biomarkers of epithelial injury (CC16, SPD, SPA, and RAGE) were measured to assess their prognostic and predictive value. Elevated SPD levels were strongly associated with disease severity and predicted faster clinical improvement with fostamatinib treatment. SPD and CC16 levels remained stable in the fostamatinib group compared with increased levels in the placebo group over 29 days, reflecting alveolar recovery and improved epithelial integrity. SPA and RAGE showed no significant predictive value for clinical outcomes in this setting. CONCLUSIONS: SPD and CC16 are valuable biomarkers for assessing lung epithelial injury in severe COVID-19. These biomarkers can serve as prognostic indicators of disease severity and predictive markers of response to fostamatinib, guiding therapeutic strategies to improve outcomes in patients with severe respiratory complications.


  • SARS-CoV-2 Immune Complex–Mediated Neutrophil Activation

    by Kiana C Allen, Seth Warner, Heather L Teague, Marcos J Ramos-Benitez, Rui Miao, Xin Tian, Robert Reger, Peter D Burbelo, Chi Wing (Jeffrey) Pang, Yogendra Kanthi, et al.

    Understanding disease pathogenesis is essential to developing therapies in patients with infections that cause critical illness. Herein, we show that SARS-CoV-2–specific antibody levels and markers of neutrophil activation are associated with disease severity in patients hospitalized with COVID-19. We also provide a link between the adaptive and innate immune response by demonstrating an association between antibody levels and multiple markers of neutrophil degranulation and NETosis. We further demonstrate through a series of in vitro assays that SARS-CoV-2 antigen-antibody immune complexes can stimulate NETosis. Last, we discuss how this NETosis is more strongly associated with IgA immune complexes than IgG and can be ameliorated with spleen tyrosine kinase inhibition.


  • Klebsiella pneumoniae induces dose-dependent shock, organ dysfunction, and coagulopathy in a nonhuman primate critical care model

    by Jeffrey R. Strich, Marcos J. Ramos-Benitez, Seth Warner, Heather Kendall, Sydney Stein, Andrew P. Platt, Sabrina C. Ramelli, Shelly J. Curran, Izabella Lach, Kiana Allen, et al.

    Nonhuman primate models that closely emulate the disease course, pathogenesis, and supportive care provided to human patients in the modern intensive care unit with bacterial sepsis are urgently needed to study pathogenesis and assess novel therapies. We therefore developed a non-human primate model of septic shock that includes supportive care akin to a modern intensive care unit. In this study, we characterized pathogen kinetics and evaluated the physiologic, immunologic, and pathologic responses in this model of septic shock induced by the clinically relevant pathogen Klebsiella pneumoniae across a three-log dose range. We observed dose-dependent bacteremia and circulating levels of Klebsiella pneumoniae DNA and endotoxin. Tachycardia and hypotension occurred in all animals and the study endpoint occurred in 8 of 12 animals that were euthanized. The infused bacterial dose was significantly associated with the severity of renal insufficiency and coagulopathy. Neutrophil activation evidenced by increased CD11b expression, decreased CD62L expression, and increased circulating levels of myeloperoxidase, lactoferrin, and neutrophil extracellular traps; monocyte activation evidenced by increased circulating levels of interleukin-6, tumor necrosis factor-alpha, granulocyte-macrophage colony-stimulating factor, and monocyte chemotactic protein-1; and endothelial activation evidenced by increased circulating levels of syndecan-1 and angiopoietin-II were all consistent with human sepsis. Our model provides an opportunity to study pathogenesis and investigate novel therapeutics for the treatment of bacterial sepsis in the setting of modern supportive care. IMPORTANCE: There is currently a disconnect between the efficacy of sepsis therapies in pre-clinical animal models and human clinical trials. Therefore, developing nonhuman primate models that closely mimic human sepsis pathogenesis to study novel host-targeted therapeutics is a priority. In this study, we developed a model of septic shock with a clinically relevant bacteria ( Klebsiella pneumoniae ) that provides standard supportive care including mechanical ventilation, invasive hemodynamic monitoring, volume resuscitation, vasopressors, antibiotics, and steroids. In a dose-dependent manner, we observed that this model closely emulates the hemodynamic, end-organ dysfunction, and cellular and soluble responses associated with human sepsis. This validated model provides a unique opportunity to study the pathogenesis of acute septic shock and evaluate host-directed therapeutics in a large animal model that closely emulates the modern-day intensive care unit and supportive critical care.


  • Open Access

    R406 reduces lipopolysaccharide-induced neutrophil activation

    by Seth Warner, Heather L. Teague, Marcos J. Ramos-Benitez, Sumith Panicker, Kiana Allen, Salina Gairhe, Tom Moyer, Bindu Parachalil Gopalan, Iyadh Douagi, Arun Shet, et al.


  • Open Access

    1110. Why has Utilization of Novel Gram-negative Antibiotics been Sluggish in U.S. Hospitals? A Retrospective Cohort Study to Inform Future Antibiotic Development and Market Entry Rewards

    by Jeffrey R Strich, Ahmed Ullah Mishuk, Alexander Lawandi, Guoqing Diao, Sarah Warner, Willy Li, Cumhur Y Demirkale, Alex Mancera, Morgan Walker, Christina Yek, et al.

    Sluggish uptake of novel gram-negative antibiotics has jeopardized their future development and supply potentially risking patient lives. Understanding underutilization patterns might better inform unmet needs and market entry rewards. We studied patterns and drivers of use of recently U.S. FDA-approved novel gram-negative agents in patients with gram-negative infections (GNI) displaying difficult-to-treat resistance (DTR; resistance to all first line B-lactams including carbapenems, and fluoroquinolones). Using the all-payer PINC-AI database, quarterly percent change in the post-approval use of seven gram-negative agents and secular trends in colistin use were calculated. For inpatients with DTR GNI at microbiology reporting hospitals, we compared novel vs older/reserve agent use by infection site and pathogen. At hospitals that use novel agents, generalized linear mixed models with weighting identified patient and hospital factors associated with the use of any novel (vs older/reserve) agents as targeted therapy against DTR GNI. Nearly half the patients in US hospital with DTR-GNIs are still receiving targeted therapy with older/reserve agents. While the value of novel agents is indicated by clinicians preferring them over older/reserve agents in sicker patients, future agents with distinctly novel mechanisms and activity against DTR-A. baumannii are needed to bridge the utilization gap. Morgan Walker, MD, Cytovale: Advisor/Consultant